

[Meet the Professor]

18th Meet The Professor Advanced International Breast Cancer Course (AIBCC)

Padova e online, November 3-4, 2022



[Preliminary Program]

Thursday, November 3rd

10.15 Introduction to the Conference
Pier Franco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat

SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION

Chairpersons: Hesham Ahmed Gaballah Elghazaly, Aleix Prat

- 10.30 Biological heterogeneity and clinical outcomes in HR+/HER2-negative disease Maria Vittoria Dieci
- 11.00 PDL1, TMB, TROP2, immune infiltration and genomic classifiers in TNBC Giampaolo Bianchini
- 11.30 Is HER2-low breast cancer a real entity? Scoring issues and biological heterogeneity Giuseppe Viale
- 12.00 HER2+ early breast cancer: potential role of genomic classifiers Aleix Prat
- 12.30 Q&A
- 13.00 Lunch

SESSION II – CHANGING PARADIGMS FOR LOCOREGIONAL TREATMENTS Mastectomy, breast reconstruction and radiation Therapy

Chairpersons: Jaceck Jassem, Philip Poortmans

- 14.00 When is breast-conserving therapy really not avoidable Oreste Gentilini
- 14.30 Breast reconstruction: when and how? Vincenzo Vindigni
- 15.00 Radiation therapy after breast reconstruction Orit Kaidar-Person
- 15.30 Q&A

Multidisciplinary Tumor Board 1 – Locoregional treatment

Panelists: Bettina Borisch, Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas, Orit Kaidar-Person, Philip Poortmans, Fedro Peccatori

- 16.00 Clinical case 1. Second breast conserving therapy Tania Saibene
- 16.15 Clinical case 2. Patient with lymph node seen on planning CT-scan: what now? (RT) Silvia Michieletto
- 16.30 Clinical case 3. BRCA carrier after mastectomy and immediate breast reconstruction? TBD
- 16.45 Clinical case 4: BOOP: after or due to radiation therapy Alessandro Parisi



Sandra Swain

17.00	Concluding comments: Eleftherios Mamounas, Fedro Peccatori
17.20	Adjourn
17.45	Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2022
18.00	Lecture of the Awardee
18.30	Adjourn
Friday	, November 4 th
	SESSION III – EARLY BREAST CANCER. FINE TUNING FROM DE-ESCALATION TO ESCALATION
	Chairpersons: Michelino De Laurentiis, Miguel Martin
9.00	Tailoring neoadjuvant/adjuvant treatment for triple negative breast cancer Sibylle Loibl
9.30	Risk adapted treatment of early HR+/HER2- breast cancer: from modulation of endocrine treatment to novel agents Stephen Johnston
10.00	Is there a role for anthracyclines in contemporary treatment of early breast cancer? Valentina Guarneri
10.30	Q&A
11.00	Coffee Break
	Multidisciplinary Tumor Board 2 - Early breast cancer Panelists: Bettina Borisch, Michelino de Laurentiis, Valentina Guarneri, Jacek Jassem, Stephen Johnston, Sibylle Loibl, Miguel Martin, Fedro Peccatori
11.30	Clinical case 1. Node positive, premenopausal patient: role of genomic classifiers - Cristina Falci
11.45	Clinical case 2. HR+HER2+ patient with residual disease after neoadjuvant therapy - Federica Miglietta
12.00	Clinical case 3. Adjuvant treatment in rare histologies - Grazia Vernaci
12.15	Concluding comments: Jaceck Jassem, Miguel Martin
12.30	Lunch
	SESSION IV – METASTATIC BREAST CANCER: NEW OPTIONS, NEW ALGORITHMS Chairpersons: Pierfranco Conte, Bettina Borisch
13.30	HER2+ advanced breast cancer: new treatment algorithms



- 14.00 TN advanced breast cancer: biology-driven treatment algorithms Hope Rugo
- 14.30 HR+ advanced breast cancer: what after CDK4/6? Giuseppe Curigliano
- 15.00 Q&A

Multidisciplinary Tumor Board 3 - Metastatic Breast Cancer

Panelists: Bettina Borisch, Pierfranco Conte, Giuseppe Curigliano, Hesham Ahmed Gaballah Elghazaly, Hope Rugo, Sandra Swain

- 15.30 Clinical case 1. Brain metastases Gaia Griguolo
- 15.45 Clinical case 2. Possibility of discontinuing treatment in very long term responders Carlo Alberto Giorgi
- 16.00 Clinical case 3. Locoregional treatment for oligometastatic disease or role of NGS in ABC Michele Bottosso
- 16.15 Concluding comments: Pierfranco Conte, Hesham Ahmed Gaballah Elghazaly
- 16.30 Take home messages and adjourn

[Aims]

Mortality from breast cancer is declining in most countries thanks to effective screening programs, early diagnosis, molecular characterization of the different subtypes and biology-driven treatments. A multidisciplinary management of breast cancer patients is therefore the key to success and a breast multidisciplinary team should include - besides the "classic" clinical specialties - pathologists, molecular biologists and geneticists. Furthermore, the availability of multiple diagnostic and therapeutic choices, the increasing costs of new technologies and drugs and the issue of sustainability represent a new challenge for socially-responsible clinicians. With this goal in mind, the Programme includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes and issues of sustainability and drug access across countries.

[Addressed to]

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

[Honorary President]

Gabriel N. Hortobagyi Department of Breast Medical Oncology The University of Texas - MD Anderson Cancer Center Houston (USA)



[Directors]

Pierfranco Conte Rete Oncologica Veneta Molecular Tumor Board, Rete Oncologica Veneta Scientific Director Istituto Oncologico Veneto IRCCS Padova

Valentina Guarneri Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)

Philip Poortmans
Former president of ESTRO and of ECCO
Department of Radiation Oncology
Iridium Netwerk
University of Antwerp
Wilrijk-Antwerp (B)

Aleix Prat Medical Oncology Department Hospital Clinic Barcellona (E)

[Scientific Committee]

Bettina Borisch Institute of Global Health University of Geneva

Maria Vittoria Dieci Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)

Hesham Ahmed Gaballah Elghazaly Department of Clinical Oncology and nuclear medicine University of Ainshams Cairo (EG)

Jacek Jassem
Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)

Stephen Johnston NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK)



Sibylle Loibl German Breast Group University of Frankfurt (D)

Eleuterios Mamounas Comprehensive Breast Program MD Anderson Cancer Center Orlando Orlando (F)

Miguel Martin Medical Oncology Service Hospital Universitario Gregorio Marañon Madrid (E)

Fedro Alessandro Peccatori Department of Medical Oncology European Institute of Oncology (IEO) Milano (I)

Sandra Swain M. Research Development Georgetown University Medical Center Washington (USA)

[Speakers]

Giampaolo Bianchini Breast Unit IRCC S. Raffaele Hospital Milano (I)

Michele Bottosso Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)

Giuseppe Curigliano Department of Oncology European Institute of Oncology University of Milan (I)

Michelino De Laurentiis Breast Unit IRCCS Istituto Nazionale Tumori Fondazione G. Pascale Napoli

Maria Vittoria Dieci Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)



Cristina Falci
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Valentina Guarneri Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)

Oreste Davide Gentilini Breast Unit IRCC S. Raffaele Hospital Milano (I)

Carlo Alberto Giorgi
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Gaia Griguolo
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Orit Kaidar-Person Breast Cancer Radiation Therapy Unit Sheba Medical Center Ramat Gan (IL)

Stephen Johnston NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK)

Sibylle Loibl German Breast Group University of Frankfurt (D)

Silvia Michieletto
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)



Federica Miglietta
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Alessandro Parisi
Department of Radiation Oncology
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Aleix Prat Medical Oncology Department Hospital Clinic Barcellona (E)

Hope Rugo Breast Oncology Clinical Trials Program UCSF Carol Franc Buck Breast Care Center San Francisco (USA)

Tania Saibene Breast Surgery Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

Sandra Swain M. Research Development Georgetown University Medical Center Washington (USA)

Grazia Vernaci
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Giuseppe Viale Department of Pathology European Institute of Oncology University of Milan (I)

Vincenzo Vindigni Breast Surgery Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)



[Meeting Venue]

Auditorium Centro Culturale San Gaetano Altinate Via Altinate, 71 Padova

Website address: https://fad.accmed.org/